Toronto Innovation Acceleration Partners
Investments
25Funds
4Partners & Customers
10About Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners (TIAP) specializes in venture building of early-stage health science technologies emerging from our members. Toronto Innovation Acceleration Partners (TIAP) is a member-driven not-for-profit organization which was created in 2008 (at that time under the name "MaRS Innovation") by 13 of Toronto's top universities, institutions and research institutes, plus the MaRS Discovery District as host organization. Its mandate is to bring the members' most promising research breakthroughs to market. In addition to member support, early funding came from the Federal Government through the Centres of Excellence for Commercialization and Research program.
Toronto Innovation Acceleration Partners Headquarter Location
661 University Avenue Suite 465
Toronto, Ontario, M5G 1M1,
Canada
647-260-7869
Toronto Innovation Acceleration Partners Web Traffic
Toronto Innovation Acceleration Partners Rank
Latest Toronto Innovation Acceleration Partners News
Nov 23, 2021
The UTEST Program provides support to University of Toronto entrepreneurs to create research based companies. In partnership with Toronto Innovation Acceleration Partners (TIAP) and with the financial support of the Connaught Fund, it provides companies with investment capital, mentoring, business strategy and incubation space at the University of Toronto St. George Campus. We wish to acknowledge this land on which the University of Toronto operates. For thousands of years it has been the traditional land of the Huron-Wendat, the Seneca, and the Mississaugas of the Credit. Today, this meeting place is still the home to many Indigenous people from across Turtle Island and we are grateful to have the opportunity to work on this land. Subscribe to
Toronto Innovation Acceleration Partners Investments
25 Investments
Toronto Innovation Acceleration Partners has made 25 investments. Their latest investment was in MedMe Health as part of their Seed VC - II on March 3, 2022.
Toronto Innovation Acceleration Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/17/2022 | Seed VC - II | MedMe Health | $2.7M | Yes | Graphite Ventures, M12, and Y Combinator | 4 |
9/21/2021 | Seed VC | PhenoTips | $1.95M | Yes | GreenSky Capital, Thin Air Labs, Undisclosed Angel Investors, and Yorkville Partners | 9 |
2/8/2018 | Convertible Note | Zucara Therapeutics | No | 1 | ||
12/21/2017 | Seed VC | |||||
3/20/2017 | Series A |
Date | 3/17/2022 | 9/21/2021 | 2/8/2018 | 12/21/2017 | 3/20/2017 |
|---|---|---|---|---|---|
Round | Seed VC - II | Seed VC | Convertible Note | Seed VC | Series A |
Company | MedMe Health | PhenoTips | Zucara Therapeutics | ||
Amount | $2.7M | $1.95M | |||
New? | Yes | Yes | No | ||
Co-Investors | Graphite Ventures, M12, and Y Combinator | GreenSky Capital, Thin Air Labs, Undisclosed Angel Investors, and Yorkville Partners | |||
Sources | 4 | 9 | 1 |
Toronto Innovation Acceleration Partners Fund History
4 Fund Histories
Toronto Innovation Acceleration Partners has 4 funds, including MaRS Innovation - Pfizer Translational Research Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
4/9/2018 | MaRS Innovation - Pfizer Translational Research Fund | $0.63M | 1 | ||
12/12/2014 | MaRS Impact Venture Fund | ||||
3/26/2012 | MaRS Cleantech Fund | ||||
5/31/2011 | GSK-MaRS Innovation Fund |
Closing Date | 4/9/2018 | 12/12/2014 | 3/26/2012 | 5/31/2011 |
|---|---|---|---|---|
Fund | MaRS Innovation - Pfizer Translational Research Fund | MaRS Impact Venture Fund | MaRS Cleantech Fund | GSK-MaRS Innovation Fund |
Fund Type | ||||
Status | ||||
Amount | $0.63M | |||
Sources | 1 |
Toronto Innovation Acceleration Partners Partners & Customers
10 Partners and customers
Toronto Innovation Acceleration Partners has 10 strategic partners and customers. Toronto Innovation Acceleration Partners recently partnered with Amgen on September 9, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
9/12/2019 | Partner | United States | TIAP TIAP Announces Strategic Partnership with Amgen - TIAP `` Amgen is enthusiastic about this strategic partnership with TIAP , '' added Francesco Di Marco , Vice President and General Manager of Amgen . | 2 | |
6/19/2018 | Partner | Germany | Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics - Evotec Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics LP . | 1 | |
4/9/2018 | Client | United States | $800,000 MaRS Innovation–Pfizer Translational Research Fund MaRS Innovation is thrilled to continue our long-standing collaboration with Pfizer Inc. ; a partnership with a focus on translating the highly qualified research coming from our 15 member institutions . | 1 | |
12/21/2017 | Partner | ||||
11/28/2017 | Partner |
Date | 9/12/2019 | 6/19/2018 | 4/9/2018 | 12/21/2017 | 11/28/2017 |
|---|---|---|---|---|---|
Type | Partner | Partner | Client | Partner | Partner |
Business Partner | |||||
Country | United States | Germany | United States | ||
News Snippet | TIAP TIAP Announces Strategic Partnership with Amgen - TIAP `` Amgen is enthusiastic about this strategic partnership with TIAP , '' added Francesco Di Marco , Vice President and General Manager of Amgen . | Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics - Evotec Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics LP . | $800,000 MaRS Innovation–Pfizer Translational Research Fund MaRS Innovation is thrilled to continue our long-standing collaboration with Pfizer Inc. ; a partnership with a focus on translating the highly qualified research coming from our 15 member institutions . | ||
Sources | 2 | 1 | 1 |
Toronto Innovation Acceleration Partners Team
2 Team Members
Toronto Innovation Acceleration Partners has 2 team members, including current Chief Executive Officer, President, Parimal Nathwani.
Name | Work History | Title | Status |
|---|---|---|---|
Parimal Nathwani | Chief Executive Officer, President | Current | |
Raphael Hofstein | Chief Executive Officer, President | Former |
Name | Parimal Nathwani | Raphael Hofstein |
|---|---|---|
Work History | ||
Title | Chief Executive Officer, President | Chief Executive Officer, President |
Status | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.